Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM.

Kong MF, King P, Macdonald IA, Stubbs TA, Perkins AC, Blackshaw PE, Moyses C, Tattersall RB

Diabetologia1 Jan 1997Cited by 97 (Europe PMC)

PMID9028722DOI10.1007/s001250050646PepBankPUB-09028722

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with IDDM, pramlintide increased liquid gastric emptying lag time versus placebo.
In plain wordsIn men with IDDM, pramlintide delayed liquid emptying from the stomach compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseLiquid gastric emptying lag time
Study
n = 8
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
25 micrograms/h · infusion · 5 hAs given in this study (human).
Measurements
Median liquid lag time
69 min
pramlintide
Median liquid lag time
7.5 min
placebo
Source sentences
Summary
Compared to placebo, pramlintide significantly delayed emptying of both liquid (median lag time 69 vs 7.5 min) and solid (median lag time 150 vs 44.5 min) components of the meal.
2 context sentences(design, population, supporting numbers)
Summary · context
Eight men with uncomplicated IDDM were studied twice in a randomised, double-blind crossover design.
Summary · context
Euglycaemia was maintained overnight by intravenous infusion of glucose and/or insulin and the following morning a 5-h infusion of pramlintide 25 micrograms/h or placebo was started at 08.00 hours.
Report a problemFND-0902872201
02HumanRandomized controlled trialEfficacy outcome
In men with IDDM, pramlintide increased solid gastric emptying lag time versus placebo.
In plain wordsIn men with IDDM, pramlintide delayed solid emptying from the stomach compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseSolid gastric emptying lag time
Study
n = 8
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
25 micrograms/h · infusion · 5 hAs given in this study (human).
Measurements
Median solid lag time
150 min
pramlintide
Median solid lag time
44.5 min
placebo
Source sentences
Summary
Compared to placebo, pramlintide significantly delayed emptying of both liquid (median lag time 69 vs 7.5 min) and solid (median lag time 150 vs 44.5 min) components of the meal.
2 context sentences(design, population, supporting numbers)
Summary · context
Eight men with uncomplicated IDDM were studied twice in a randomised, double-blind crossover design.
Summary · context
Euglycaemia was maintained overnight by intravenous infusion of glucose and/or insulin and the following morning a 5-h infusion of pramlintide 25 micrograms/h or placebo was started at 08.00 hours.
Report a problemFND-0902872202
03HumanRandomized controlled trialEfficacy outcome
In men with IDDM, pramlintide delayed gastric emptying so much that t50 could not be calculated for solid or liquid components.
In plain wordsIn men with IDDM, pramlintide delayed stomach emptying so much that half-emptying time could not be calculated for solid or liquid.
Peptide
Pramlintide (Symlin)
Outcome
Direction not reportedGastric emptying t50 (solid and liquid)
Study
n = 8
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
25 micrograms/h · infusion · 5 hAs given in this study (human).
Source sentences
Summary
Pramlintide delayed gastric emptying so much that t50 values could not be calculated for solid or liquid.
2 context sentences(design, population, supporting numbers)
Summary · context
Eight men with uncomplicated IDDM were studied twice in a randomised, double-blind crossover design.
Summary · context
Euglycaemia was maintained overnight by intravenous infusion of glucose and/or insulin and the following morning a 5-h infusion of pramlintide 25 micrograms/h or placebo was started at 08.00 hours.
Report a problemFND-0902872203

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.